mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

  • STATUS
    Recruiting
  • days left to enroll
    22
  • participants needed
    1407
  • sponsor
    Cambridge University Hospitals NHS Foundation Trust
Updated on 22 June 2021
covid-19
SARS

Summary

TACTIC-E is a randomised, parallel arm, open-label platform trial for investigating potential treatments for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID-19 appears to be due to a later, exaggerated, host immune response (Gralinski and Baric 2015). This leads to lung and sometimes multi-organ damage.

Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. This study will assess the efficacy of a novel immunomodulatory agent and a novel combination of approved agents which may protect the patient against end-organ damage and modulate the pulmonary vascular response. This study will compare the novel therapeutic agent EDP1815 and a novel combination of the approved agents dapagliflozin and ambrisentan against Standard of Care.

Description

TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 and a combination of the approved cardiovascular drugs dapagliflozin and ambrisentan as potential treatments for COVID-19 disease against Standard of Care alone. These agents target the dysregulated immune response that drive the severe lung, and other organ, damage frequently seen during COVID-19 infection, with an aim to promote a positive vascular response to reduce end-organ damage.

Treatment with EDP1815 will be for up to 7 days, with the option of extension to 14 days at the discretion of the PI or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Treatment with combination dapagliflozin and ambrisentan will be for up to 14 days. Patients will be randomised in a 1:1:1 ratio across treatments.

TACTIC-E will use a platform design with interim analysis to make efficient decisions about efficacy and futility (e.g. lack of efficacy and risk of harm) of the trial treatments. This enables the trial to stop recruiting to arms early where a clear efficacy decision can be made. It also allows for the addition of further arms.

Details
Condition *COVID-19, Covid-19
Treatment Standard of Care, Dapagliflozin, Ambrisentan, EDP1815
Clinical Study IdentifierNCT04393246
SponsorCambridge University Hospitals NHS Foundation Trust
Last Modified on22 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Be aged 18 and over
Have clinical picture strongly suggestive of COVID-19-related disease (with/without positive COVID-19 test) AND
Risk count (as defined below) >3 OR
Risk count 3 if it includes "Radiographic severity score >3
Be hospitalized or eligible for hospitalization on clinical grounds
Be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator

Exclusion Criteria

Inability to supply direct informed consent from patient or from Next of Kin or Independent Healthcare Provider on behalf of patient
Invasive mechanical ventilation at time of screening
Contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients
Currently on any of the study investigational medicinal products
Concurrent participation in an interventional clinical trial (observational studies allowed)
Patient moribund at presentation or screening
Pregnancy at screening
Unwilling to stop breastfeeding during treatment period
Known severe hepatic impairment (with or without cirrhosis)
Inability to swallow at screening visit
Requiring dialysis Cockcroft Gault estimated creatinine clearance < 30 ml /min/1.73m2 at screening
Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern
EDP1815-Specific Exclusion Criteria
Patient is taking a systemic immunosuppressive agent such as, but not limited to, oral steroids, methotrexate, azathioprine, ciclosporin or tacrolimus, unless these are given as part of COVID standard of care treatment
Patient has known primary or secondary B cell disorder
Dapagliflozin- and Ambrisentan-Specific Exclusion Criteria
Type 1 diabetes
Known idiopathic pulmonary fibrosis
Previous hospital admission with ketoacidosis
History of symptomatic heart failure within 3 months of admission
Patients concurrently on other SGLT2 inhibitors
Sustained blood pressure below 100/70 mmHg at admission
Metabolic acidosis defined as pH< 7.25 AND ketones > 3.0 mmol/L
Alanine transaminase and/or aspartate transaminase (ALT and/or AST) > 3 times the upper limit of normal (only one needs to be measured)
Risk Count
Patients will be given a Risk Count equal to the cumulative points received
for the following criteria (no = 0 points, yes = 1 point)
Male gender, Age > 40 years, Non-white ethnicity, Diabetes, Hypertension
Neutrophils > 8.0x10^9/L, CRP > 40mg/L, Radiographic severity score >3
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note